EACS2023: 336 Real-life data of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed women with VIH-1. G. Pousada , L. Buzón , J. Troya , R. Micán , C. Galera , I. Santos , J. Sanz , C. Martín , M.Á. Garcinuño , M.J. Galindo , N. Cabello , R. Pedrero-Tomé , C. Dueñas Hospital Álvaro Cunqueiro, Vigo, Spain, Hospital de Burgos, Burgos, Spain, Hospital Universitario Infanta Leonor, Madrid, Spain, Hospital Universitario La Paz, Madrid, Spain, Hospital L´Arrixaca Murcia, Murcia, Spain, Hospital Universitario La Princesa, Madrid, Spain, Hospital Príncipe de Asturias, Madrid, Spain, Complejo Asistencial de Zamora, Zamora, Spain, Complejo Asistencial de Ávila, Ávila, Spain, Hospital Clínico de Valencia, Valencia, Spain, Hospital Clínico de Madrid, Madrid, Spain, Fundación de Investigación e Innovación del Hospital Universitario Infanta Leonor y del Sureste, Madrid, Spain, Hospital de Valladolid, Valladolid, Spain General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has become a gold standard for people living with HIV (PLWH) with high efficacy and safety rates in long-term data of clinical trials. However, data regarding efficacy and immune status restoration in women are needed. Method: We performed a multicenter, non-controlled, retrospective study of pretreated and suppressed women switching to B/F/TAF. We evaluated the efficacy and immune status at 48 and 96 weeks after the switch. Results: The study comprised 376 women from 13 hospitals in Spain, with a median age of 53.0 [45.0 – 58.0] years. The median time of HIV infection was 22.0 [13.3 – 29.0] years. AIDS diagnoses were made in 27.8% of cases. Virological failure was registered in 3 (0.07%) patients [available data of viral suppression at 48 weeks in 320 patients: 95.8% (<50 copies/ml) and at 96 weeks in 260 patients: 96.7 (<50 copies/ml)]. In virological failures, no resistance mutations were found. other discontinuations included 23 simplifications (10.6), 18 toxicity issues (8.7), 6 drug-to-drug interactions (2.9), and loss of follow-up (1%). Median CD4 at switching to B/F/TAF was 725 [517 - 950]. In week 48, we found a decrease in CD8+ count of -29 cells/mm (-255–141) and an increase in CD4+ count of 31 (-120–155), and in week 96, a decrease in CD8+ count of -17 cells/mm (-225–162) and an increase in CD4+ count of 31 (-158–213). CD4/CD8 ratio increased by 0.08 (-0.10– 0.15) in week 48. In AIDS-diagnosed patients, a significant decrease in the CD8+ count of -25 (-257–131) cells/mm was found at week 48 and week 96 of -57 (-244–216) cells/mm ; p<0.001. Conclusions: B/F/TAF achieved high efficacy rates in long-term virologically-controlled women and slightly improved immune status during weeks 48 and 96 after switching. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 3 4 5 6 7 8 9 10 11 12 13 1 2 3 4 5 6 7 8 9 10 11 12 13 3 3 3 3 104 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=